Tarsus Pharmaceuticals’ (TARS) “Buy” Rating Reiterated at HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Tuesday, TipRanks reports. They currently have a $40.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 201.66% from the stock’s current price.

Several other research firms have also recently commented on TARS. Zacks Investment Research raised Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 24th. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $55.00 to $66.00 in a research note on Monday. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $48.00.

TARS traded down $0.74 on Tuesday, hitting $13.26. 17,633 shares of the company’s stock were exchanged, compared to its average volume of 37,710. Tarsus Pharmaceuticals has a fifty-two week low of $13.49 and a fifty-two week high of $39.08. The company has a market capitalization of $274.61 million, a PE ratio of -18.32 and a beta of 1.44. The firm’s 50-day simple moving average is $17.94.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last posted its quarterly earnings results on Monday, March 14th. The company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.05. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $7.11 million. Tarsus Pharmaceuticals had a negative net margin of 24.25% and a negative return on equity of 7.66%. As a group, equities analysts anticipate that Tarsus Pharmaceuticals will post -4.02 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 1.7% during the 4th quarter. BlackRock Inc. now owns 448,958 shares of the company’s stock worth $10,101,000 after purchasing an additional 7,338 shares during the period. Goldman Sachs Group Inc. boosted its stake in Tarsus Pharmaceuticals by 6.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 28,103 shares of the company’s stock worth $632,000 after buying an additional 1,623 shares during the period. State Street Corp increased its position in shares of Tarsus Pharmaceuticals by 2.3% during the fourth quarter. State Street Corp now owns 129,742 shares of the company’s stock valued at $2,919,000 after acquiring an additional 2,940 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 125,815 shares of the company’s stock valued at $2,830,000 after acquiring an additional 2,117 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Tarsus Pharmaceuticals by 21.2% in the 4th quarter. Ensign Peak Advisors Inc now owns 242,451 shares of the company’s stock valued at $5,456,000 after acquiring an additional 42,451 shares during the period. Institutional investors own 70.00% of the company’s stock.

About Tarsus Pharmaceuticals (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Further Reading